Stem Cell Therapeutic and Research Reauthorization Act of 2015 became law 183 days after introduction, with cosponsors from both parties
Written by the Congressional Research Service [2]. 174 words.
(This measure has not been amended since it was reported to the Senate on December 3, 2015. The summary of that version is repeated here.) Stem Cell Therapeutic and Research Reauthorization Act of 2015
(Sec. 2) This bill amends the Public Health Service Act and the Stem Cell Therapeutic and Research Act of 2005 to revise and extend through FY2020 the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory program. (These programs help match patients in need of a transplant with unrelated bone marrow and cord blood donors.) The Department of Health and Human Services (HHS) must review the state of the science of using adult stem cells and birthing tissues to develop new therapies and consider the inclusion of new therapies in the C.W. Bill Young Cell Transplantation Program.
(Sec. 3) Requirements for HHS contracts under the Stem Cell Therapeutic and Research Act of 2005 are revised.
(Sec. 4) HHS must determine whether to include peripheral blood stem cells and umbilical cord blood in the definition of human organ.
- Committees
- House Energy and Commerce Committee
Senate Health, Education, Labor, and Pensions Committee - Policy area
- Health: 122 of 9,357 bills became law, 113th–118th (1.3%)
- Sponsor
- 15 of 282 bills enacted since 2013
- Text versions
- 8, from enrolled bill to public law · 924 words
- Subjects
- Administrative law and regulatory proceduresBlood and blood diseasesCell biology and embryologyDepartment of Health and Human ServicesHealth programs administration and fundingMedical research +3 more
- Latest action
- Dec 18, 2015: Became Public Law No: 114-104.
- Records
- Congress.gov · Bill text
Each bill appears once, under its strongest link. 1 in all.
Related, per CRS or House · 1
- 114th S. 2282 Stem Cell Therapeutic and Research Reauthorization Act of 2015 R · Introduced